These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 22029979)

  • 1. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.
    Palefsky JM; Giuliano AR; Goldstone S; Moreira ED; Aranda C; Jessen H; Hillman R; Ferris D; Coutlee F; Stoler MH; Marshall JB; Radley D; Vuocolo S; Haupt RM; Guris D; Garner EI
    N Engl J Med; 2011 Oct; 365(17):1576-85. PubMed ID: 22029979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
    Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Inquiry: Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men?
    Shum J; Kelsberg G; Safranek S
    J Fam Pract; 2015 Sep; 64(9):581-3. PubMed ID: 26546954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia.
    Deshmukh AA; Chiao EY; Das P; Cantor SB
    Vaccine; 2014 Dec; 32(51):6941-6947. PubMed ID: 25444820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
    Hidalgo-Tenorio C; Ramírez-Taboada J; Gil-Anguita C; Esquivias J; Omar-Mohamed-Balgahata M; SamPedro A; Lopez-Ruz M; Pasquau J
    AIDS Res Ther; 2017 Jul; 14(1):34. PubMed ID: 28720147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.
    Hillman RJ; Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Vardas E; Aranda C; Jessen H; Ferris DG; Coutlee F; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI
    Clin Vaccine Immunol; 2012 Feb; 19(2):261-7. PubMed ID: 22155768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men.
    Deshmukh AA; Chhatwal J; Chiao EY; Nyitray AG; Das P; Cantor SB
    Clin Infect Dis; 2015 Nov; 61(10):1527-35. PubMed ID: 26223993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Human Papillomavirus Vaccine: Current Perspective and Future Role in Prevention and Treatment of Anal Intraepithelial Neoplasia and Anal Cancer.
    Mensah FA; Mehta MR; Lewis JS; Lockhart AC
    Oncologist; 2016 Apr; 21(4):453-60. PubMed ID: 26961923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.
    Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Penny ME; Aranda C; Vardas E; Moi H; Jessen H; Hillman R; Chang YH; Ferris D; Rouleau D; Bryan J; Marshall JB; Vuocolo S; Barr E; Radley D; Haupt RM; Guris D
    N Engl J Med; 2011 Feb; 364(5):401-11. PubMed ID: 21288094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
    FUTURE II Study Group
    N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.
    Kreimer AR; González P; Katki HA; Porras C; Schiffman M; Rodriguez AC; Solomon D; Jiménez S; Schiller JT; Lowy DR; van Doorn LJ; Struijk L; Quint W; Chen S; Wacholder S; Hildesheim A; Herrero R;
    Lancet Oncol; 2011 Sep; 12(9):862-70. PubMed ID: 21865087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298.
    Wilkin TJ; Chen H; Cespedes MS; Leon-Cruz JT; Godfrey C; Chiao EY; Bastow B; Webster-Cyriaque J; Feng Q; Dragavon J; Coombs RW; Presti RM; Saah A; Cranston RD
    Clin Infect Dis; 2018 Oct; 67(9):1339-1346. PubMed ID: 29659751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Human Papillomavirus Vaccine Against Anal Human Papillomavirus Infection, Anal Intraepithelial Neoplasia, and Recurrence of Anal Intraepithelial Neoplasia: A Systematic Review and Meta-analysis.
    Wei F; Alberts CJ; Albuquerque A; Clifford GM
    J Infect Dis; 2023 Nov; 228(11):1496-1504. PubMed ID: 37257044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
    Joura EA; Giuliano AR; Iversen OE; Bouchard C; Mao C; Mehlsen J; Moreira ED; Ngan Y; Petersen LK; Lazcano-Ponce E; Pitisuttithum P; Restrepo JA; Stuart G; Woelber L; Yang YC; Cuzick J; Garland SM; Huh W; Kjaer SK; Bautista OM; Chan IS; Chen J; Gesser R; Moeller E; Ritter M; Vuocolo S; Luxembourg A;
    N Engl J Med; 2015 Feb; 372(8):711-23. PubMed ID: 25693011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
    N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study.
    Swedish KA; Factor SH; Goldstone SE
    Clin Infect Dis; 2012 Apr; 54(7):891-8. PubMed ID: 22291111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298.
    Cranston RD; Cespedes MS; Paczuski P; Yang M; Coombs RW; Dragavon J; Saah A; Godfrey C; Webster-Cyriaque JY; Chiao EY; Bastow B; Wilkin T;
    Sex Transm Dis; 2018 Apr; 45(4):266-271. PubMed ID: 29528986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Wheeler CM; Skinner SR; Del Rosario-Raymundo MR; Garland SM; Chatterjee A; Lazcano-Ponce E; Salmerón J; McNeil S; Stapleton JT; Bouchard C; Martens MG; Money DM; Quek SC; Romanowski B; Vallejos CS; Ter Harmsel B; Prilepskaya V; Fong KL; Kitchener H; Minkina G; Lim YKT; Stoney T; Chakhtoura N; Cruickshank ME; Savicheva A; da Silva DP; Ferguson M; Molijn AC; Quint WGV; Hardt K; Descamps D; Suryakiran PV; Karkada N; Geeraerts B; Dubin G; Struyf F;
    Lancet Infect Dis; 2016 Oct; 16(10):1154-1168. PubMed ID: 27373900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.